No Prescription |
 |
 | ||
|
DUOLIN HFA Combivent |
|
| ||
No Prescription » Prescription Drugs 6 » DUOLIN HFA Combivent Ipratropium (i-pra-TROE-pee-um) and albuterol (al-BYOO-ter-ol) combination is a bronchodilator (medicine that opens up narrowed breathing passages). It is taken by inhalation to help control the symptoms of lung diseases such as asthma chronic bronchitis and emphysema.Ipratropium in combination with albuterol helps decrease coughing wheezing shortness of breath and troubled breathing by increasing the flow of air into the lungs.Duolin is prescribed for people with chronic obstructive pulmonary disease (COPD) if they are already taking one airway-opening medication and need another. The product's two active ingredients act in distinctly different ways. Ipratropium quells airway-closing spasms in the bronchial walls. Albuterol relaxes the muscles in the walls permitting them to expand. When used together the two ingredients provide more relief than either can do alone.Duolin is supplied in an aerosol canister for use only with the special Combivent mouthpiece.Albuterol and ipratropium are bronchodilators that relax muscles in the airways and increase air flow to the lungs.The combination of albuterol and ipratropium inhalation is used to prevent bronchospasm in people with chronic obstructive pulmonary disease (COPD) who are also using other medicines to control their condition. Buy DUOLIN HFA Combivent and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About DUOLIN HFA Combivent: Product Type: Prescription Drugs 6 DUOLIN HFA ( Combivent Duoneb Generic Ipratropium & Salbutamol ) DUOLIN HFA (Combivent Duoneb Generic Ipratropium & Salbutamol) Combivent Duoneb Generic Ipratropium & Salbutamol 20/100mcg 4 Inhalers (200 MD) Inhaler (200 MD) Combivent Duoneb Generic Ipratropium & Salbutamol DUOLIN HFA
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
